TIZIANA LIFE SCIENCES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6227 USD | -2.70% |
|
-16.42% | +11.20% |
Presenter SpeechUnknown Analyst (Analysts)Our next presenter is a biotechnology company that f...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.20% | 62.46M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Transcript : Tiziana Life Sciences PLC Presents at LD Micro 500 Virtual Investor Conference, Sep-02-2020 02